Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Allied Healthcare Group Adds Former CSL Executive’S Expertise To Board

Allied Healthcare Group (ASX: AHZ) has appointed former CSL executive and general counsel Peter Turvey as a non-executive director.

Turvey worked at CSL, a biopharmaceutical company that develops and manufactures vaccines and plasma protein biotherapies, for 19 years.

He was initially appointed as the first corporate counsel before being appointed company secretary in 1998.

During his time at CSL, Turvey played a major role as part of the executive team that built CSL into the international company it is today.

He was also responsible for the management and licensing of CSL's intellectual property portfolio and overseeing risk management for the group.

Turvey was involved in many licensing deals, most notably the HPV vaccine Gardasil licence to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to several of the world's leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.

He is currently a principal at Foursight Associates and a non-executive director of listed biotechnology company Starpharma Holding, as well as a director of industry organisation Ausbiotech.

Turvey replaces Handojo (Jet) Soedirdja, who is retiring from the board.

Chris Catlow, chairman of Allied Healthcare Group, commented on the appointment:

"Peter's experience building a global healthcare business as well has his licensing background will be a great benefit to the Allied Healthcare Group board."

Allied recently increased its shareholding in investment company Coridon after investing a further A$1 million.

This is a strategic move for the company, giving Allied a 44.4% share in Coridon and maintaining its focus on unique drug programs with global implications.

Coridon is rapidly advancing towards its Phase I study for a herpes vaccine and is making further progress on its Human Papillomavirus (HPV) therapeutic vaccine program.

Less than two weeks prior to announcing it had increased its stake in Coridon, Allied Healthcare revealed Coridon had gained access to vector technology that will improve the performance of its next generation of DNA vaccines.

Coridon has entered into a licence agreement with Nature Technology Corporation for the use of its safe, minimalised and antibiotic-free selection vectors.

Proactive Investors is a market leader in the investment news space, providing ASX "Small and Mid-cap" company news, research reports, StockTube videos and One2One Investor Forums.